New Scancell Holdings Plc (LON:SCLP) chief sets out his vision to commercialise groundbreaking cancer treatments: Proactive Investors Stocktube

Published on 15 Feb 2018

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company. 

Holloway says generating clinical data's a big focus for them in the near-term. ''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''. 

 ''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''. 

 ''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

https://www.scancell.co.uk

http://www.4-traders.com/SCANCELL-HOLDINGS-PLC-6451111/